Advice

Following a full submission

rotigotine (Neupro) is accepted for use within NHS Scotland for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults.

It should only be used in patients with a baseline score of 15 points or more on the International Restless Legs Scale (IRLS). Compared with placebo, rotigotine was associated with improvements on a patient-administered scale based on the core clinical features of the syndrome and on the incidence of periodic limb movements during time in bed.

Other dopamine agonists licensed for use in RLS are available at a lower cost.

Download detailed advice82KB (PDF)

Download

Medicine details

Medicine name:
rotigotine (Neupro)
SMC ID:
548/09
Indication:
Restless Legs Syndrome (RLS)
Pharmaceutical company
UCB Pharma Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Accepted
Date advice published
10 August 2009